IMTX Stock: Price, Earnings History and SEC Filings
Immatics N.V. (IMTX) last traded at $7.20, down 1.50% on the latest session and down 18.0% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $-0.53 against an analyst estimate of $-0.43, a miss of 23.3%.
$7.20 -1.50%
1 month-18.00%
52-week high$12.41
52-week low$6.65
Volume1.72M
ExchangeNasdaqCM
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
IMTX earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 18, 2026 | $-0.53 | $-0.43 | -23.26% |
| Mar 2026 | May 12, 2026 | $-0.50 | $-0.42 | -19.05% |
| Dec 2025 | Mar 5, 2026 | $-0.34 | $-0.48 | +29.17% |
| Sep 2025 | Nov 17, 2025 | $-0.49 | $-0.50 | +2.00% |
IMTX beat the analyst EPS estimate in 2 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for IMTX
SEC filing data is not available right now. You can search for IMTX on SEC EDGAR.
IMTX news
- Immatics (IMTX) PRAME Data Puts A Pricey Valuation Back In FocusNov 1, 2026 · finance.yahoo.com
- Bristol Myers Squibb (BMY) Q3 Earnings and Revenues Beat EstimatesOct 29, 2026 · finance.yahoo.com
- Immatics (IMTX) Stock Looks Stretched As PRAME Trial Data ImpressesOct 29, 2026 · finance.yahoo.com
- Immatics Posts Strong PRAME-Targeted Data for IMA402 and IMA203CD8 at 2026 ESMOOct 27, 2026 · theglobeandmail.com
- Should Updated Trial Results Require Action From Immatics (IMTX) Investors?Oct 25, 2026 · finance.yahoo.com
- Immatics Presents Clinical Activity of IMA402 PRAME Bispecific and IMA203CD8 PRAME Cell Therapy across Advanced Solid Tumors in Two Oral Presentations at 2026 ESMO Annual MeetingOct 24, 2026 · finance.yahoo.com
About Immatics N.V.
Immatics N.V. (IMTX) is a US-listed public company on Nasdaq.